目的:探讨术前炎性指标与早期非小细胞肺癌术后患者预后的相关性及系统性免疫炎性指标指导早期非小细胞肺癌术后患者后续治疗方案的可行性.方法:我们收集了30例2014年至2015年于徐州医科大学附属医院行肺癌根治术的早期非小细胞肺癌(Ⅰ期-Ⅱ期)患者(实验组)的术前血液学指标(同期30例体检合格者为对照组),并计算嗜中性粒细胞计数/淋巴细胞计数(NLR)、血小板计数/淋巴细胞计数(PLR)、血小板计数和嗜中性粒细胞计数/淋巴细胞计数(SII)、预后营养指数(PNI)、血浆血清乳酸脱氢酶(LDH)、平均血细胞容积(MCV).比较亚组间各炎性指标的差异.结果:实验组患者的白蛋白水平、MCV、PNI低于对照组患者;SII高于对照组患者.Ⅰ期患者的中性粒细胞计数、SII低于Ⅱ期患者;白蛋白水平、PNI高于Ⅱ期患者.SD组患者的中性粒细胞计数、NLR、PLR、SII低于PD组患者;MCV高于PD组患者.SII≥400的高水平组患者无进展生存率、无进展生存时间均显著低于SII＜ 400的低水平组患者.结论:术前炎性指标SII有助于预测早期非小细胞肺癌术后患者的预后,对于术前SII≥400的早期非小细胞肺癌患者术后应当采取更加积极的治疗措施.%Objective:To investigate the correlation of preoperative inflammation index and prognosis of early non -small cell lung cancer patients undergoing radical operation,and to investigate the feasibility of SII guiding follow-up treatment options for postoperative early non-small cell lung cancer patients.Methods:The hematology indexes of 30 patients with early NSCLC(stage Ⅰ-Ⅱ) undergoing radical operation from 2014 to 2015 in The Affiliated Hospital of Xuzhou Medical University were gathered,and the inflammatory indexes such as NLR,PLR,SII,PNI,LDH,MCV were developed.The differences of these indexes between different subgroups were compared.Results:The level of albumin,MCV and PNI in experimental group were significantly lower than that in control group.The level of SII in experimental group was higher than that in control group.The level of neutrophils count and SII of the NSCLC patients with TNM stage of I stage were lower than those of Ⅱ stage.The level of albumin and PNI of the NSCLC patients with TNM stage of Ⅰ stage were higher than those of Ⅱ stage.The level of neutrophils count,NLR,PLR and SII of the NSCLC patients of stable disease were lower than those of progressive disease.The level of MCV of the NSCLC patients of stable disease were higher than those of progressive disease.The radio and time of progression free survival of the NSCLC patients of SII ≥400 were lower than those of the NSCLC patients of SII ＜ 400.Conclusion:Preoperative SII was conducive to predict the prognosis of patients after radical operation for early non-small cell lung cancer.The NSCLC patients of SII≥400 should take a more active treatment.
展开▼
